Erwei Song

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4453630/publications.pdf

Version: 2024-02-01

111 papers	16,061 citations	36303 51 h-index	31849 101 g-index
114 all docs	114 docs citations	114 times ranked	20876 citing authors

#	Article	IF	Citations
1	let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell, 2007, 131, 1109-1123.	28.9	1,762
2	RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Medicine, 2003, 9, 347-351.	30.7	1,091
3	Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery, 2019, 18, 99-115.	46.4	1,040
4	Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy, 2020, 5, 8.	17.1	998
5	Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnology, 2005, 23, 709-717.	17.5	967
6	CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell, 2018, 172, 841-856.e16.	28.9	831
7	A Cytoplasmic NF-Î²B Interacting Long Noncoding RNA Blocks IÎ²B Phosphorylation and Suppresses Breast Cancer Metastasis. Cancer Cell, 2015, 27, 370-381.	16.8	794
8	A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis. Cancer Cell, 2014, 25, 605-620.	16.8	607
9	Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer, 2011, 10, 117.	19.2	596
10	CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3. Cancer Cell, 2011, 19, 541-555.	16.8	530
11	DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature, 2020, 583, 133-138.	27.8	491
12	Extracellular vesicle-packaged HIF-1Î±-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nature Cell Biology, 2019, 21, 498-510.	10.3	488
13	NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nature Immunology, 2018, 19, 1112-1125.	14.5	337
14	Sustained Small Interfering RNA-Mediated HumanImmunodeficiency Virus Type 1 Inhibition in PrimaryMacrophages. Journal of Virology, 2003, 77, 7174-7181.	3.4	231
15	Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death and Disease, 2019, 10, 55.	6.3	215
16	miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nature Communications, 2015, 6, 8523.	12.8	203
17	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell, 2018, 175, 442-457.e23.	28.9	198
18	Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends in Immunology, 2022, 43, 523-545.	6.8	176

#	Article	IF	Citations
19	Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 ⁺ Breast Cancer Growth and Metastasis. Science Translational Medicine, 2012, 4, 130ra48.	12.4	163
20	Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Research, 2017, 27, 461-482.	12.0	163
21	Simultaneous overactivation of Wnt/Î²-catenin and TGFÎ² signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. Nature Communications, 2017, 8, 15870.	12.8	159
22	Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. Cell, 2020, 180, 1081-1097.e24.	28.9	153
23	Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Molecular Cancer, 2020, 19, 65.	19.2	143
24	Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomicsâ€“Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer. JAMA Network Open, 2020, 3, e2028086.	5.9	130
25	Long noncoding RNA lnc-TSI inhibits renal fibrogenesis by negatively regulating the TGF-Î²/Smad3 pathway. Science Translational Medicine, 2018, 10, .	12.4	129
26	LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nature Communications, 2020, 11, 5513.	12.8	116
27	Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer, 2016, 16, 320.	2.6	115
28	LncRNA NKILA suppresses TGFâ€Î²â€induced epithelialâ€“mesenchymal transition by blocking NFâ€ÎºB signaling in breast cancer. International Journal of Cancer, 2018, 143, 2213-2224.	5.1	108
29	Local Recurrence of Benign, Borderline, and Malignant Phyllodes Tumors of the Breast: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2019, 26, 1263-1275.	1.5	104
30	Long non-coding RNA NKILA inhibits migration and invasion of tongue squamous cell carcinoma cells via suppressing epithelial-mesenchymal transition. Oncotarget, 2016, 7, 62520-62532.	1.8	102
31	Tamoxifen enhances stemness and promotes metastasis of ERÎ±36+ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Research, 2018, 28, 336-358.	12.0	98
32	CK1Î± suppresses lung tumour growth by stabilizing PTEN and inducing autophagy. Nature Cell Biology, 2018, 20, 465-478.	10.3	97
33	Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nature Communications, 2020, 11, 1456.	12.8	91
34	The HIF-1Î± antisense long non-coding RNA drives a positive feedback loop of HIF-1Î± mediated transactivation and glycolysis. Nature Communications, 2021, 12, 1341.	12.8	91
35	Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nature Communications, 2018, 9, 1595.	12.8	89
36	Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. , 2020, 8, e000696.		88

#	Article	IF	Citations
37	Treatments for Idiopathic Granulomatous Mastitis: Systematic Review and Meta-Analysis. Breastfeeding Medicine, 2017, 12, 415-421.	1.7	85
38	BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nature Communications, 2014, 5, 5406.	12.8	84
39	Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cellular and Molecular Immunology, 2020, 17, 451-461.	10.5	83
40	The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation. Cell Reports, 2015, 11, 111-124.	6.4	80
41	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nature Communications, 2018, 9, 1614.	12.8	76
42	Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/Î²-catenin signaling. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14019-14028.	7.1	72
43	Nonmuscle myosin heavy chain IIA mediates Epsteinâ€“Barr virus infection of nasopharyngeal epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11036-11041.	7.1	70
44	Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Network Open, 2020, 3, e202149.	5.9	69
45	Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stemâ€“like Cell Traits in Breast Cancer. Cancer Research, 2014, 74, 3603-3616.	0.9	68
46	Targeting CAFs to overcome anticancer therapeutic resistance. Trends in Cancer, 2022, 8, 527-555.	7.4	68
47	MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3. Molecular Cancer, 2015, 14, 96.	19.2	67
48	Terbium-doped gadolinium oxide nanoparticles prepared by laser ablation in liquid for use as a fluorescence and magnetic resonance imaging dual-modal contrast agent. Physical Chemistry Chemical Physics, 2015, 17, 1189-1196.	2.8	66
49	Role of curcumin in the management of pathological pain. Phytomedicine, 2018, 48, 129-140.	5.3	66
50	E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. Oncotarget, 2015, 6, 31944-31957.	1.8	62
51	Noncoding RNAs: New Players in Cancers. Advances in Experimental Medicine and Biology, 2016, 927, 1-47.	1.6	61
52	MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stemâ€“like Cells and Breast Tumor Development. Cancer Research, 2014, 74, 6648-6660.	0.9	59
53	NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-Î¹B pathway inhibition. PLoS Genetics, 2019, 15, e1008325.	3.5	58
54	Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5pâ€“MFF axis. Oncotarget, 2015, 6, 14885-14904.	1.8	50

#	Article	IF	Citations
55	Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: A NCDB analysis. Oncotarget, 2015, 6, 40127-40140.	1.8	48
56	Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation. Cancer Research, 2017, 77, 3605-3618.	0.9	44
57	EGF-induced nuclear localization of SHCBP1 activates Î²-catenin signaling and promotes cancer progression. Oncogene, 2019, 38, 747-764.	5.9	44
58	Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. EBioMedicine, 2016, 11, 199-209.	6.1	43
59	CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget, 2015, 6, 20485-20499.	1.8	43
60	The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells. Journal of the National Cancer Institute, 2020, 112, 356-368.	6.3	42
61	Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. Nature Immunology, 2021, 22, 865-879.	14.5	41
62	The theory of tumor ecosystem. Cancer Communications, 2022, 42, 587-608.	9.2	40
63	MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-Î² pathway in NSCLC. Oncogene, 2019, 38, 896-912.	5.9	39
64	Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis. Oncotarget, 2016, 7, 10373-10385.	1.8	37
65	Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals. Oncologist, 2020, 25, e1473-e1480.	3.7	34
66	Long Noncoding RNA Expression Signatures of Metastatic Nasopharyngeal Carcinoma and Their Prognostic Value. BioMed Research International, 2015, 2015, 1-13.	1.9	33
67	Genotoxic stress-triggered Î²-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. Nature Communications, 2019, 10, 3761.	12.8	33
68	Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nature Communications, 2020, 11, 5842.	12.8	33
69	PIK3CÎ´ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 2020, 130, 3188-3204.	8.2	33
70	Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nature Communications, 2022, 13, .	12.8	33
71	Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. JCO Precision Oncology, 2020, 4, 244-257.	3.0	32
72	The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells. Protein and Cell, 2016, 7, 89-99.	11.0	31

#	Article	IF	Citations
73	Poly(<scp>ADP</scp> â€ribosyl)ation of <scp>BRD</scp> 7 by <scp>PARP</scp> 1 confers resistance to <scp>DNA</scp> â€damaging chemotherapeutic agents. EMBO Reports, 2019, 20, .	4.5	31
74	The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. Nature Cancer, 2021, 2, 457-473.	13.2	31
75	Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. Journal of Biological Chemistry, 2017, 292, 748-759.	3.4	28
76	circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. Molecular Cancer, 2022, 21, 8.	19.2	28
77	Benign Phyllodes Tumor of the Breast Diagnosed After Ultrasound-Guided Vacuum-Assisted Biopsy: Surgical Excision or Wait-and-Watch?. Annals of Surgical Oncology, 2016, 23, 1129-1134.	1.5	25
78	Discovery of CCL18 antagonist blocking breast cancer metastasis. Clinical and Experimental Metastasis, 2019, 36, 243-255.	3.3	23
79	Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages. OncoImmunology, 2014, 3, e953418.	4.6	22
80	Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget, 2015, 6, 18683-18692.	1.8	20
81	RNF219/Î±â€Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications. Advanced Science, 2021, 8, 2001961.	11.2	19
82	Deep sequencing reveals a global reprogramming of lncRNA transcriptome during EMT. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1703-1713.	4.1	18
83	Non-coding RNAs rewire cancer metabolism networks. Seminars in Cancer Biology, 2021, 75, 116-126.	9.6	17
84	Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 331-370.	1.6	16
85	ATMâ€Dependent Recruitment of BRD7 is required for Transcriptional Repression and DNA Repair at DNA Breaks Flanking Transcriptional Active Regions. Advanced Science, 2020, 7, 2000157.	11.2	16
86	Circumferential Shaving of the Cavity in Breast-Conserving Surgery: A Randomized Controlled Trial. Annals of Surgical Oncology, 2019, 26, 4256-4263.	1.5	14
87	PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling. Oncogene, 2022, 41, 2749-2763.	5.9	14
88	Mammary stem cells: angels or demons in mammary gland?. Signal Transduction and Targeted Therapy, 2017, 2, 16038.	17.1	13
89	Noncoding RNAs: biology and applicationsâ€”a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, 1506, 118-141.	3.8	13
90	A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Oncotarget, 2016, 7, 87312-87322.	1.8	12

#	Article	IF	Citations
91	Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment. Molecular Cancer Therapeutics, 2017, 16, 775-786.	4.1	11
92	Comparison of breast-conserving surgery and mastectomy in early breast cancer using observational data revisited: a propensity score-matched analysis. Science China Life Sciences, 2018, 61, 1528-1536.	4.9	11
93	The variation degree of coagulation function is not responsible for extra risk of hemorrhage in gestational diabetes mellitus. Journal of Clinical Laboratory Analysis, 2020, 34, e23129.	2.1	8
94	Cancer stem cells: advances in biology and clinical translationâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, 1506, 142-163.	3.8	8
95	Long non-coding RNA and non-coding nucleic acids: Signaling players in the networks of the tumor ecosystem. , 2022, 1, 100004.		8
96	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Science China Life Sciences, 2022, 65, 2205-2217.	4.9	7
97	In pursuit of a flawless aphrodite: paving the way to scarless oncoplastic breast surgery. Cancer Communications, 2019, 39, 82.	9.2	6
98	Ductal Lavage for Patients With Nonlactational Mastitis: A Single-Arm, Proof-of-Concept Trial. Journal of Surgical Research, 2019, 235, 440-446.	1.6	5
99	Introduction of a multicenter online database for non-metastatic breast cancer in China. Science China Life Sciences, 2020, 63, 1417-1420.	4.9	5
100	Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, 1066-1066.	1.6	4
101	Overexpression of PITPNM3 promotes hepatocellular carcinoma cell metastasis. Science Bulletin, 2014, 59, 1326-1333.	1.7	3
102	Pinched by RNA â€œfingersâ€• Long noncoding RNAs hitting signal transduction pathways. Molecular and Cellular Oncology, 2016, 3, e1046582.	0.7	2
103	Insights into artificial intelligence in clinical oncology: opportunities and challenges. Science China Life Sciences, 2022, 65, 643-647.	4.9	1
104	Abstract 6123: High-fat diets promote lung metastasis of breast cancer by activating lung fibroblasts. Cancer Research, 2022, 82, 6123-6123.	0.9	1
105	The Dawning of Translational Breast Cancer: From Bench to Bedside. Advances in Experimental Medicine and Biology, 2017, 1026, 1-25.	1.6	0
106	ASO Author Reflections: Local Recurrence Risk and Risk Factors of Breast Phyllodes Tumors. Annals of Surgical Oncology, 2019, 26, 637-638.	1.5	0
107	Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, 532-532.	1.6	0
108	Modulating lncRNA NKILA in tumor-reactive T cells to enhance their trafficking to breast cancer by inhibition of FasL-induced T-cell apoptosis.. Journal of Clinical Oncology, 2017, 35, 143-143.	1.6	0

#	Article	IF	Citations
109	Conversion of CCL18-recruited naÃ¯ve CD4+ T cells to tumor-infiltrating regulatory T cells in breast cancer and suppression of antitumor immunity.. Journal of Clinical Oncology, 2017, 35, 114-114.	1.6	0
110	Tumor associated macrophages antagonize antitumor effect of chemotherapy.. Journal of Clinical Oncology, 2017, 35, 120-120.	1.6	0
111	A novel oral paclitaxel and HM10381 (oraxel)-treated metastatic breast cancer: A phase I study (KX-ORAX-CN-007).. Journal of Clinical Oncology, 2022, 40, 1104-1104.	1.6	0